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SYSTEMATIC REVIEW AND META-ANALYSIS
Specific Therapy for Transthyretin Cardiac 
Amyloidosis: A Systematic Literature Review 
and Evidence-Based Recommendations
Nuno Marques , MD; Olga Azevedo , MD; Ana Rita Almeida, MD; Dina Bento, MD; Inês Cruz, MD;  
Emanuel Correia, MD; Carolina Lourenço, MD; Luís Rocha Lopes, PhD
BACKGROUND: The emergence of specific therapies for transthyretin cardiac amyloidosis (CA) warrants the need for a system-
atic review of the literature.
METHODS AND RESULTS: A systematic review of the literature was conducted according to Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A systematic search was performed on MEDLINE, PubMed, 
and Embase databases on November 29, 2019. Studies were selected based on the following predefined eligibility criteria: 
English-language randomized controlled trials (RCTs), non-RCTs, or observational studies, which included adult patients with 
variant/wild-type transthyretin-CA, assessed specific therapies for transthyretin-CA, and reported cardiovascular outcomes. 
Relevant data were extracted to a predefined template. Quality assessment was based on National Institute for Health and 
Care Excellence recommendations (RCTs) or a checklist by Downs and Black (non-RCTs). From 1203 records, 24 publications 
were selected, describing 4 RCTs (6 publications) and 16 non-RCTs (18 publications). Tafamidis was shown to significantly 
improve all-cause mortality and cardiovascular hospitalizations and reduce worsening in 6-minute walk test, Kansas City 
Cardiomyopathy Questionnaire—Overall Summary score, and NT-proBNP (N-terminal pro-B-type natriuretic peptide) in vari-
ant/wild-type transthyretin-CA. Patisiran showed promising results in a subgroup analysis of patients with variant transthyre-
tin-CA, which have to be confirmed in RCTs. Inotersen showed conflicting results on cardiac imaging parameters. The one 
study on AG10 had only a 1-month duration and cardiovascular end points were exploratory and limited to cardiac biomarkers. 
Limited evidence from noncomparative single-arm small non-RCTs existed for diflunisal, epigallocatechin-3-gallate (green tea 
extract), and doxycycline+tauroursodeoxycholic acid/ursodeoxycholic acid.
CONCLUSIONS: This systematic review of the literature supports the use of tafamidis in wild-type and variant transthyretin-CA. 
Novel therapeutic targets including transthyretin gene silencers are currently under investigation.
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Transthyretin-related amyloidosis (ATTR) results from the tissue deposition of amyloid fibers that are composed of transthyretin, a protein that is 
mainly produced by the liver and acts as a carrier of 
thyroxine and retinol-binding protein bound to retinol.1 
Fibrillogenesis requires the dissociation of transthyretin 
tetramers into misfolded monomers that self-assem-
ble in soluble oligomeric species. Oligomers aggregate 
into protofibrils and finally mature amyloid fibers, which 
then deposit within tissues leading to the development 
of ATTR.1 ATTR can result from the deposition of either 
variant ATTR (ATTRv) or wild-type ATTR (ATTRwt).2
ATTRv is an autosomal dominant disease and >120 
pathogenic variants, mostly missense, have been de-
scribed in the transthyretin gene. The phenotype is 
variable, ranging from pure polyneuropathy to selec-
tive cardiac involvement.2 Accurate statistics on the 
prevalence of ATTRv are difficult to obtain. Among 
Americans of European descent, the estimated in-
cidence of ATTRv is 0.4 per million people per year; 
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however, this condition is believed to be more common 
among people with African ancestry and in specific 
geographic areas, such as northern Portugal, Sweden, 
Japan, or some regions of West Africa.2 In Portugal, 
endemic ATTRv is caused by the Val30Met mutation 
and familial amyloidotic polyneuropathy is the predom-
inant feature of the phenotype.
ATTRwt is characteristically associated with almost 
exclusive cardiac involvement, with carpal tunnel syn-
drome being one of the few extracardiac red flags. The 
true prevalence of ATTRwt is unknown, but it may be 
relatively high compared with the prevalence of ATTRv.3 
It affects the elderly and, in autopsy studies, nearly 
25% of the hearts of individuals aged 80 years or older 
contained wild-type transthyretin fibrils, regardless of 
the presence of symptoms.3 Studies using nonbiopsy 
approaches to diagnose ATTRwt reported prevalence 
rates of 16% among patients undergoing percutane-
ous aortic valve replacement for severe aortic stenosis, 
13% among patients with heart failure with preserved 
ejection fraction, 5% among patients with presumed 
hypertrophic cardiomyopathy, and 7% to 8% among 
patients with carpal tunnel syndrome on biopsy of the 
tenosynovial tissue. Furthermore, 1% to 3% of individ-
uals older than 75 years showed myocardial retention 
of diphosphono-1,2-propanodicarboxylic acid, which 
is indicative of TTR-related cardiac amyloidosis (CA).3
Cardiac involvement is common in ATTR and is 
associated with a particularly poor life expectancy 
of 2 to 6 years after diagnosis. Transthyretin CA is a 
progressive disorder and patients ultimately develop 
heart failure, dysrhythmias, and cardiac conduction 
disturbances, which result in decreased functional 
capacity, diminished quality of life, and eventually 
death.3 Moreover, treatment of transthyretin CA was, 
until recently, limited to the treatment of symptoms and 
complications.
However, the emergence of new therapeutic op-
tions and the results of recent randomized controlled 
trials in patients with transthyretin CA warrant the need 
for a systematic review of the literature.
The aim of the systematic review was to identify and 
synthesize the available evidence on specific therapies 
for transthyretin CA and, based on this, to provide ev-
idence-based recommendations for the use of these 
therapies. This systematic review will focus on spe-
cific therapies targeting the inhibition of transthyretin 
synthesis (inotersen or patisiran); tetramer stabilization 
(diflunisal, tafamidis, or AG10); inhibition of oligomer 
aggregation and disruption (epigallocatechin-3-gal-
late); and degradation and reabsorption of amyloid fi-
bers (doxycycline-tauroursodeoxycholic [TUDCA] acid 
or doxycycline-ursodeoxycholic acid [UDCA]).4
METHODS
The authors declare that all supporting data are avail-
able within the article.
This systematic review of the literature was con-
ducted using the methodology suggested by Preferred 
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines.5 It was conducted in 
3 stages: a comprehensive and systematic search of 
the published literature to identify all potentially relevant 
studies; systematic selection of relevant studies based 
on explicit inclusion and exclusion criteria; and ex-
traction of relevant data from eligible studies to assess 
the effects of therapy in patients with transthyretin CA.
CLINICAL PERSPECTIVE
What Is New?
• As novel therapies emerge in the field of tran-
sthyretin-related amyloidosis, this systematic 
review of the literature examines and presents 
the existing evidence regarding specific thera-
pies for transthyretin cardiac amyloidosis.
• This systematic review supports the use of 
tafamidis in patients with transthyretin cardiac 
amyloidosis, either variant transthyretin-related 
amyloidosis or wild-type transthyretin-related 
amyloidosis, but does not support the use of di-
flunisal, AG10, doxycycline, or epigallocatechin-
3-gallate in these patients.
What Are the Clinical Implications?
• Novel therapies, including transthyretin gene 
silencers, are currently under investigation in 
dedicated randomized controlled trials.
Nonstandard Abbreviations and Acronyms
ATTR transthyretin-related amyloidosis
ATTRv  variant transthyretin-related 
amyloidosis
ATTRwt  wild-type transthyretin-related 
amyloidosis
CA cardiac amyloidosis
EMA European Medicines Agency
FDA Food and Drug Administration
KCCQ-OS  Kansas City Cardiomyopathy 
Questionnaire—Overall Summary
NYHA New York Heart Association
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Search Strategy
A systematic search was performed on November 
29, 2019, in the following databases: MEDLINE, 
PubMed, and Embase. The search was performed 
in the English-language literature using the follow-
ing keywords: “transthyretin amyloidosis treatment”; 
“transthyretin amyloidosis therapy”; “AG10 transthyre-
tin amyloidosis”; “diflunisal transthyretin amyloidosis”; 
“tafamidis”; “oligonucleotides transthyretin amyloido-
sis”; “inotersen”; “patisiran”; “green tea transthyretin 
amyloidosis”; and “doxycycline transthyretin amyloido-
sis.” A deduplication step was performed to remove 
studies that overlapped among the databases.
Selection Criteria
To be included in this review, studies had to meet the 
predefined eligibility criteria listed in Table 1. In sum-
mary, studies included in this review were RCTs, non-
RCTs, or observational studies, including adult patients 
diagnosed with transthyretin CA, assessing at least 1 
of the specific therapies for transthyretin CA and re-
porting cardiovascular outcomes (Table 1).
Primary screening was performed by 2 authors 
who independently reviewed each reference (title and 
abstract) identified by the literature search, applied the 
inclusion and exclusion criteria listed in Table 1, and de-
cided on whether to include or exclude the publication 
at that stage. Disagreement regarding the inclusion of 
studies was solved by a third author. The full-text articles 
were obtained for potentially relevant studies identified 
by primary screening of titles and abstracts. These were 
independently reviewed by 2 reviewers against each el-
igibility criteria. Disagreement regarding the inclusion of 
studies was solved by a third author.
Data Extraction
The data regarding the cardiovascular outcomes of 
patients under specific therapies for transthyretin CA 
were extracted. Safety data on these therapies were 
also extracted.
The data extraction process was performed by 
one author to a predefined extraction data template 
(Tables 2 and 3) and independently checked for errors 
against the original study report by another author.
Multiple publications regarding the same patient 
population and reporting data for the same intervention 
were linked together and extracted as a single reference.
Quality Assessment
Quality assessment of the included RCTs was per-
formed using comprehensive assessment criteria 
based on recommendations in the National Institute 
for Health and Care Excellence template30 (Figure 1). 
Quality assessment of the included non-RCTs was 




Database searches identified 1203 records, of which 
495 studies were identified as duplicates and ex-
cluded. The screening of the remaining 708 studies 
Table 1. Inclusion and Exclusion Criteria of the Studies for 
Systematic Review
Category Inclusion Criteria Exclusion Criteria
Population • Patients with 
transthyretin CA
• Familial or mutant/
variant transthyretin CA




• Healthy volunteers 
only
• Pediatric population 
(<18 y)
• Disease other than 
transthyretin CA
Interventions Studies assessing specific 







• Doxycycline plus 
tauroursodeoxycholic 
acid or ursodeoxycholic 
acid
• Green tea extract 
(epigallocatechin-3-
gallate)
• Nonspecific therapies 
for ATTR such 




• Studies assessing 
interventions not 
included on the list
Comparators • No restrictions • None
Outcomes • Cardiovascular 
outcomes
◦ Biomarkers
















• Cohort studies (both 
prospective and 
retrospective)
• Systematic reviews and 
meta-analyses of RCTs*/
non-RCTs*
• Case reports, case 
series
• Pharmacokinetic and 
economic studies
• Preclinical studies
• Reviews, letters, and 
comment articles
Language • English • Other than English
ATTR indicates transthyretin-related amyloidosis; CA, cardiac amyloidosis; 
and RCT, randomized controlled trials.
*Systematic reviews and meta-analyses of RCTs and non-RCTs were 
included and flagged. Bibliographies of these systematic reviews were 





 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 4









































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 5

























































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 6







































































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 7





























































































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 8



























































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 9





















































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 10





































































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 11















































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 12

























































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 13





















































































































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 14






























































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 15























































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 16






































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 17
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 18
Marques et al Specific Therapy for Transthyretin Cardiac Amyloidosis
led to the exclusion of 644 records, mainly because 
they were review or opinion articles, natural history 
studies, or in vitro or animal research studies. The re-
maining 64 records were further assessed for their 
eligibility for this review by full-text screening, which 
resulted in the additional exclusion of 40 publications, 
mainly because of the absence of reported cardiovas-
cular outcomes. Relevant data were then extracted 
from 24 publications, namely 4 RCTs reported in 6 
publications and 16 non-RCTs reported in 18 arti-
cles. Figure 3 presents the PRISMA flow diagram of 
the studies identified in this systematic review of the 
literature.
Included Studies and Quality Assessment
A total of 4 RCTs were included in this review. The 
study characteristics of these trials are presented in 
Table 2 and their quality assessment in Figure 1.
The 4 RCTs included in this review were the following:
1. a phase III study (NEURO-TTR ) assessing inot-
ersen versus placebo and including 172 patients, 
all with ATTRv, 105 of them with CA;
2. a phase III study (APOLLO) assessing patisiran ver-
sus placebo and including 225 patients, all with 
ATTRv, 126 of them with CA7–9;
3. a phase III study (ATTR-ACT) assessing tafamidis 
versus placebo and including 441 patients with CA, 
106 with ATTRv and 335 ATTRwt10; and
4. a phase II study (NCT03458130) assessing AG10 
versus placebo and including 49 patients with CA, 
14 with ATTRv and 35 ATTRwt.11
A total of 16 non-RCTs were included in this review. 
The study characteristics of these trials are presented in 
Table 3 and their quality assessment in Figure 2.
The 16 non-RCTs included in this review were the 
following:
1. one study on inotersen, single-arm, assessing 33 
patients, 10 with ATTRv and 23 with ATTRwt12,13;
2. one study on patisiran, single-arm, assessing 27 pa-
tients, all with ATTRv14;
3. four studies on diflunisal, including 3 single-arm and 
1 comparative study of stabilizer therapy (diflunisal 
or tafamidis), assessing a total of 120 patients, with 
individualized data available from 100 patients with 
ATTRv and 7 patients with ATTRwt 15–18;
4. five studies on tafamidis, including 4 single-arm and 
1 comparative study of tafamidis with a historical 
cohort, assessing a total of 127 patients, 96 with 
ATTRv and 31 ATTRwt19–24;
5. three studies on epigallocatechin-3-gallate (green 
tea extract), all single-arm, assessing 51 patients, 10 
with ATTRv and 41 with ATTRwt25–27; and
6. two studies on doxycycline, both single-arm, as-
sessing 48 patients, 44 with ATTRv and 4 with 
ATTRwt.28,29
Results of Cardiovascular and Safety 
Outcomes
The data on the cardiovascular and safety outcomes 
that were extracted from the studies included in this re-
view are detailed in Tables 2 and 3. In this section, we 
present the main results of the studies on each specific 
therapy for transthyretin CA.
Inhibition of Transthyretin Synthesis
Inotersen
Inotersen was assessed in 1 non-RCT12,13 and 1 RCT.6











1 Yes Yes Yes Unclear
2 Yes Yes Yes Unclear
3 Yes Yes Yes No
4 Yes Yes Yes Unclear
5 Yes No Yes No
6 No No No No
7 Yes Yes Yes Yes
1. Was randomization carried out appropriately?
2. Was the concealment of treatment allocation adequate?
3. Were the groups similar at the outset of the study in terms of prognostic factors? 
4. Were the care providers, participants and outcome assessors blind to treatment allocation?
5. Were there any unexpected imbalances in drop-outs between groups?
6. Is there any evidence to suggest that the authors measured more outcomes than they reported?




 http://ahajournals.org by on N
ovem
ber 2, 2020
J Am Heart Assoc. 2020;9:e016614. DOI: 10.1161/JAHA.120.016614 19
Marques et al Specific Therapy for Transthyretin Cardiac Amyloidosis
Figure 2. Quality assessment of non-randomized controlled trials (RCTs).













































































































































1 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
2 Yes Yes Yes No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
3 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
4 Yes Yes Yes Yes No Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes
5 No Yes Yes Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
6 No Yes Yes U U No Yes Yes No Yes Yes No Yes Yes No No
7 No No Yes Yes Yes No No Yes Yes Yes No No Yes Yes No No
8 Yes Yes No Yes No No Yes No Yes Yes Yes No No No No No
9 Yes No Yes Yes No Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
10 No No Yes Yes Yes Yes No No Yes No Yes No No No No No
11 Yes Yes No No Yes No No No Yes No No Yes Yes Yes No No
12 Yes Yes Yes No Yes No No No No No No Yes Yes Yes No No
13 No Yes No No No No Yes No Yes No No No No No U U
14 No No No No No No No No No No No No No No No No
15 No No No No No No No No No No No No Yes Yes No No
16 U U U U No U Yes U No No U No U U U No
17 No No No Yes Yes Yes No No No No Yes No No No No No













































































































































19 U Yes U U U U U U U U U Yes U U U U
20 Yes Yes Yes U Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes
21 NA NA NA NA Yes NA NA NA NA NA Yes NA NA NA NA NA
22 NA NA NA NA Yes NA NA NA NA NA No NA NA NA NA NA
23 No No No No No No No No No No No No No No No No
24 No No No No No No No No No No No No No No No No
25 No No No No Yes No No No No No No No No No No No
26 No No U Yes U No No No No No U No No No No No
1. Is the hypothesis/aim/objective of the study clearly described?
2. Are the main outcomes to be measured clearly described in the introduction or methods section?
3. Are the characteristics of the patients included in the study clearly described?
4. Are the interventions of interest clearly described?
5. Are the distributions of principal confounders in each group of patients to be compared clearly described?
6. Are the main findings of the study clearly described?
7. Does the study provide estimates of the random variability in the data for the main outcomes?
8. Have all important adverse events that may be a consequence of the intervention been reported?
9. Have the characteristics of patients lost to follow-up been described?
10. Have actual probability values been reported (e.g. 0.035 rather than <0.05) for the main outcomes except where the probab ility value is less than 0.001?
11. Were the subjects asked to participate in the study representative of the entire population from which they were recruited?
12. Were those subjects who were prepared to participate representative of the entire population from which they were recruited?













































































































































14. Was an attempt made to blind study subjects to the intervention they have received?
15. Was an attempt made to blind those measuring the main outcomes of the intervention?
16. If any of the results of the study were based on ‘data dredging’, was this made clear?
17. In trials and cohort studies, do the analyses adjust for different lengths of follow-up of patients, or in case-control studies, is the time period between the intervention and 
outcome the same for cases and controls?
18. Were the statistical tests used to assess the main outcomes appropriate?
19. Was compliance with the intervention(s) reliable?
20. Were the main outcome measures used accurate (valid and reliable)?
21. Were the patients in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited from the same population? 
22. Were study subjects in different intervention groups (trials and cohort studies) or were the cases and controls (case-control studies) recruited over the same period of
time?
23. Were study subjects randomised to intervention groups?
24. Was the randomised intervention assignment concealed from both patients and health care staff until recruitment was complete and irrevocable?
25. Was there adequate adjustment for confounding in the analyses from which the main findings were drawn?
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The non-RCT was a prospective single-arm study, 
with a duration of 36 months, which included 33 pa-
tients treated with inotersen, 10 with ATTRv and 23 with 
ATTRwt, and reported results on cardiovascular bio-
markers (BNP), echocardiographic and CMR param-
eters, and clinical data (6-minute walk test and New 
York Heart Association [NYHA] class). The study com-
pared data at the end of the study or at 12-month fol-
low-up with baseline data. The interventricular septum 
thickness measured by echocardiography was lower 
at study end/12-month follow-up than at baseline, but 
no significant statistical difference was found on BNP, 
6-minute walk test, or other parameters (Table 3).12,13
The phase III double-blind RCT, NEURO-TTR, in-
cluded 172 patients with ATTRv, 105 of whom had 
CA, and compared inotersen with placebo, for a du-
ration of 16.5  months, reporting echocardiographic 
parameters as exploratory outcomes. In the subset of 
patients with CA, inotersen did not show a significant 
effect on the echocardiographic parameters that were 
evaluated (Table 2).6 Moreover, in patients taking inot-
ersen, there was a higher frequency of serious adverse 
events (placebo 22% versus inotersen 32%) and study 
discontinuation caused by adverse events (placebo 
2% versus inotersen 14%); and one death occurred 
related to adverse events (placebo 0% versus inot-
ersen 1%) (Table 2). The main serious adverse events 
associated with inotersen therapy were the occur-
rence of glomerulonephritis and thrombocytopenia.6
Patisiran
Patisiran was assessed in 1 non-RCT14 and 1 RCT.7–9
The non-RCT was a prospective single-arm 
study, with a duration of 24 months, which included 
Figure 3. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow 
diagram.
CV indicates cardiovascular; RCT, randomized controlled trial.
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27 patients with ATTRv treated with patisiran, 11 of 
whom had CA, and reported exploratory data on car-
diovascular biomarkers (natriuretic peptide and tro-
ponin), echocardiographic parameters, and 10-meter 
walk test. In the subgroup of patients with CA, data 
at 24 months of follow-up were compared with base-
line data, although without applying any statistical 
test (Table 3).14
The phase III double-blind RCT, APOLLO, com-
paring patisiran and placebo, with a duration of 
18 months, included 225 patients with ATTRv, 126 of 
whom had CA, and reported data for a prespecified 
analysis of the subpopulation with CA. Outcomes in-
cluded mortality and hospitalization, mortality and 
cardiac hospitalization, 10-meter walk test, cardiovas-
cular biomarkers (natriuretic peptide), and echocardio-
graphic parameters. This subgroup analysis of patients 
with CA showed that patisiran, in comparison with pla-
cebo, appeared to be associated with lower mortality 
and hospitalization rate with an hazard ratio (HR) of 
0.49 (95% CI, 0.30–0.79), higher velocity in 10-meter 
walk test with a mean difference of 0.35 m/s (95% CI, 
0.24–0.47), lower NT-proBNP (N-terminal pro-B-type 
natriuretic peptide), with a ratio of fold-change of 0.45 
(95% CI, 0.34–0.59), lower left ventricular wall thick-
ness, and a better cardiac output and global longitudi-
nal strain. The results of the other parameters did not 
reach statistical significance (Table 2).7–9
No significant safety issues related to patisiran were 
found in these studies (Table 2 and Table 3).7–9,14
Tetramer Stabilization
Diflunisal
Diflunisal was assessed in 4 non-RCTs, with a small 
number of patients included in each study (between 
13 and 54 patients).15–18 Three of these studies were 
noncomparative single-arm prospective treated co-
horts, reporting cardiovascular biomarkers (natriu-
retic peptides and troponin) and echocardiographic 
parameters as exploratory end points.15,16,18 These 
studies compared data at the end of the study with 
the baseline data (follow-up of 10.8–38.0  months) 
and suggested stabilization of biomarkers and echo-
cardiographic parameters (Table  3).15,16,18 The other 
non-RCT was a retrospective study comparing pa-
tients on stabilizer therapy, diflunisal (n=13), or tafa-
midis (n=16), with patients without stabilizer therapy.17 
In this study, the stabilizer therapy was associated 
with significantly lower all-cause mortality or heart 
transplantation, although individualized data for 
each type of stabilizer was not reported (Table 3).17 
Notably, the available data for diflunisal refers mainly 
to patients with ATTRv (n=100) and less to patients 
with ATTRwt (n=7).
Studies have reported intolerance to diflunisal in 
some patients, mainly related to gastrointestinal, renal, 
and hematological adverse events (Table 3).15–18
Tafamidis
Tafamidis was assessed in 5 non-RCTs19–24 and 1 
RCT.10
Three of the non-RCTs were prospective noncom-
parative single-arm studies in patients with ATTRv, 
which included a small number of treated patients 
(between 10 and 61 patients) and reported cardio-
vascular outcomes, namely cardiac biomarkers 
(natriuretic peptides and troponin), ECG and echo-
cardiographic parameters, and, in 1 of the studies, 
NYHA class progression. These studies compared 
the data at the end of the study with the baseline 
data (follow-up of 12–36  months), and suggested 
stabilization of biomarkers, ECG and echocardio-
graphic parameters, and NYHA class in patients 
with ATTRv (Table  3). However, either no statistical 
test was applied or the outcomes were only explor-
atory.19,20,22,23 One prospective noncomparative sin-
gle-arm non-RCT in patients with ATTRwt, including 
31 patients, reported clinical outcomes (death, car-
diovascular hospitalizations, worsening heart failure, 
and 6-minute walk test), cardiovascular biomarkers 
(natriuretic peptides and troponin), and echocardio-
graphic and Holter parameters. This study compared 
data at the end of the study with baseline (follow-up 
of 12  months) regarding 6-minute walk test, car-
diovascular biomarkers, and echocardiographic 
parameters, suggesting stabilization of all of the an-
alyzed parameters with the exception of NT-proBNP, 
which showed a mean increment of 601  pg/mL in 
the 12 months (Table 3). This study also reported the 
occurrence of clinical events and new-onset brad-
yarrhythmias or tachyarrhythmias, although without 
providing any comparative analysis.21
One non-RCT compared mortality data of a pro-
spective study including 31 patients with ATTRwt 
and 4 patients with ATTRv treated with tafamidis 
with an untreated historical cohort from the TRACS 
(Transthyretin Amyloidosis Cardiac Study) registry, 
including 18 patients with ATTRwt and 11 patients 
with ATTRv. This study suggested a significantly 
higher survival in patients treated with tafamidis, 
both in the total cohort of patients and in patients 
with ATTRwt.24
The phase III double-blind RCT, ATTR-ACT, in-
cluding 441 patients, 106 with ATTRv and 335 with 
ATTRwt (76.0%), compared tafamidis 20 or 80  mg 
with placebo, for a duration of 30 months. It reported 
data on all-cause mortality and cardiovascular hos-
pitalizations as the primary outcomes and, also, clin-
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Cardiomyopathy Questionnaire—Overall Summary 
[KCCQ-OS] score), cardiovascular biomarkers (na-
triuretic peptide), and echocardiographic parameters 
as secondary outcomes. This study demonstrated 
a significant reduction in all-cause mortality with an 
HR of 0.70 (95% CI, 0.51–0.96) and cardiovascular 
hospitalizations with an HR of 0.68 (95% CI, 0.56–
0.81) in patients treated with tafamidis. Tafamidis 
also reduced the decline in 6-minute walk test and 
KCCQ-OS score and was associated with a smaller 
increase of NT-proBNP. A smaller decrease of left 
ventricular stroke volume and less worsening of cir-
cumferential and radial global strain were also noted 
in patients treated with tafamidis, but no effect was 
detected in the other echocardiographic parameters 
that were evaluated (Table 2).10
The non-RCTs reported the occurrence of some 
adverse events,19–23 but the RCT ATTR-ACT has not 
identified significant safety problems associated with 
tafamidis therapy in comparison to placebo (Tables 2 
and 3).10
AG10
A phase II double-blind RCT, with a duration of 
1 month, comparing AG10 and placebo and includ-
ing 49 patients, 14 with ATTRv and 35 with ATTRwt, 
reported safety outcomes and exploratory data of 
cardiovascular biomarkers. However, no compara-
tive statistic test was applied (Table 2). In this study 
there were no safety issues associated with AG10 
therapy (Table 2).11
Inhibition of Oligomer 
Aggregation and Disruption
Epigallocatechin-3-gallate (green tea extract)
Epigallocatechin-3-gallate (green tea extract) was as-
sessed in 3 non-RCTs,25–27 which were noncompara-
tive prospective single-arm studies, including a total 
of 51 patients, 10 with ATTRv and 41 with ATTRwt, 
with a 12-month follow-up, but in which data were 
only available for a small number of patients (from 7 to 
25 patients). Cardiovascular outcomes of these stud-
ies were cardiac biomarkers (natriuretic peptides and 
troponin) and ECG, echocardiographic, and CMR 
parameters. One study (n=14) showed that interven-
tricular septum thickness, measured by echocar-
diography, was lower at follow-up than at baseline, 
but this result was not supported by another study 
(n=25). In all studies, left ventricular mass, measured 
by CMR, was also significantly lower at follow-up 
than at baseline, although the difference was small. 
One study reported a significantly lower native T1 
time (n=7) at 12 months, although the difference was 
small and without a significant change in extracellular 
volume. All of the other analyzed parameters re-
mained stable at 12 months (Table 3).25–27
These studies have not identified significant safety 
problems associated with green tea extract therapy 
(Table 3).25–27
Degradation and Reabsorption of Amyloid Fibers
Doxycycline+TUDCA or UDCA
Doxycycline was assessed in 2 non-RCTs28,29 (1 study 
in association with TUDCA28 and 1 study in association 
with UDCA29
The 2 non-RCTs were noncomparative pro-
spective single-arm studies, including 48 patients, 
44 with ATTRv and 4 with ATTRwt.28,29 In the study 
with doxycycline and TUDCA, a stabilization of natri-
uretic peptide, interventricular septum thickness, and 
NYHA class was reported in 7 patients at 12-month 
follow-up.28 In the other study with doxycycline and 
UDCA, interventricular septum thickness remained 
stable, but proBNP levels were significantly higher at 
12 months in 14 patients (Table 3).29 Notably, data were 
available from only 21 patients.28,29
Studies have reported intolerance to doxycycline 
in some patients leading to treatment discontinuation 
(Table 3).28,29
DISCUSSION
This systematic review of the literature showed a clini-
cal benefit in cardiovascular outcomes of patients with 
transthyretin CA, either ATTRv or ATTRwt, treated with 
tafamidis. The potential benefit of patisiran in patients 
with variant transthyretin CA needs to be confirmed 
in RCTs. Further studies are needed to evaluate the 
clinical efficacy and safety of other therapies in patients 
with transthyretin CA.
This systematic review allows us to recommend, 
with a high degree of certainty, the use of tafa-
midis in transthyretin CA, both ATTRv and ATTRwt 
(Class of Recommendation I, Level of Evidence B). 
This recommendation is mainly based on the results 
of a large and well-designed phase III RCT, ATTR-
ACT.10 In this study, tafamidis significantly improved 
all-cause mortality and cardiovascular hospitaliza-
tions, reduced the decline in 6-minute walk test and 
KCCQ-OS score, and was associated with a smaller 
increase of NT-proBNP, smaller decrease of left ven-
tricular stroke volume, and less worsening of radial 
and circumferential global strain in patients with CA, 
caused by ATTRv or ATTRwt. Of note, in the sub-
group analysis of ATTR-ACT, the occurrence of car-
diovascular hospitalizations was not significantly 
different between tafamidis and placebo in the sub-
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noted that the study had no statistical power to draw 
conclusions from the subgroups and the P interac-
tion was not significant. In ATTR-ACT,10 tafamidis 
use was safe. Based on the available evidence, the 
use of tafamidis was approved in adults with trans-
thyretin CA (ATTRwt and ATTRv) by the Food and 
Drug Administration (FDA) in 2019 and the European 
Medicines Agency (EMA) in February 2020.
This systematic review of the literature also sug-
gests that patisiran is a promising drug for patients 
with variant transthyretin CA.
This hypothesis is mainly based on a subgroup anal-
ysis of a phase III double-blind RCT, APOLLO,7–9 which 
suggested that treatment with patisiran in these pa-
tients was associated with a reduction in mortality and 
hospitalization, as well as a reduction in NT-proBNP 
and left ventricular wall thickness and less worsening 
in cardiac output, global longitudinal strain, and 10-
meter walk test. In APOLLO,7–9 patisiran use was safe, 
without significant adverse events. The potential bene-
fit of patisiran in patients with variant transthyretin CA is 
currently under investigation in the APOLLO-B phase 
3 RCT. Moreover, there are no available data so far to 
support the use of patisiran in patients with CA caused 
by ATTRwt and results on these patients will also be 
provided by the ongoing APOLLO-B trial. Patisiran is 
currently only approved by the EMA and FDA in adults 
with ATTRv-related polyneuropathy.
Further studies will be needed to evaluate the effect 
of inotersen in patients with transthyretin CA, as data 
in the only 2 studies were contradictory, with 1 non-
RCT12,13 showing an improvement of the exploratory 
outcome of interventricular septum thickness mea-
sured by echocardiography, and 1 RCT, the NEURO-
TTR trial,6 showing an absence of significant effect on 
the echocardiographic parameters in the subgroup of 
patients with CA caused by ATTRv. Inotersen, in the 
NEURO-TTR trial,6 was also associated with the oc-
currence of severe adverse events, namely glomerulo-
nephritis and thrombocytopenia. Inotersen is currently 
only approved by the EMA and FDA in adults with 
ATTRv-related polyneuropathy.
Similarly, the use of diflunisal cannot be recom-
mended at the present time in patients with trans-
thyretin CA, because the studies on diflunisal15,16,18 
are all noncomparative small non-RCTs, including 
almost exclusively patients with ATTRv, with explor-
atory cardiovascular end points limited to cardiovas-
cular biomarkers and echocardiographic parameters. 
Furthermore, intolerance to diflunisal has been re-
ported in some patients, mainly related to gastroin-
testinal, renal, and hematological adverse events. The 
use of diflunisal in transthyretin CA is not currently ap-
proved by the EMA or FDA.
Similarly, AG10 cannot be recommended at the 
present time for transthyretin CA, as the only study of 
AG1011 had a short duration of 1 month and the cardio-
vascular end points are merely exploratory and limited 
to cardiac biomarkers. Accordingly, the use of AG10 in 
transthyretin CA is not currently approved by the EMA 
or FDA.
Although a small but significant benefit was found 
on cardiac MRI parameters such as left ventricular 
mass and native T1 in patients with transthyretin CA 
treated with epigallocatechin-3-gallate (green tea ex-
tract), these results should be interpreted carefully, as 
they are based on noncomparative single-arm small 
non-RCTs.25–27 Therefore, the use of epigallocate-
chin-3-gallate cannot be recommended at the present 
time, in transthyretin CA. The EMA and FDA also did 
not approve the use of epigallocatechin-3-gallate in 
transthyretin CA.
Similarly, results on doxycycline+TUDCA or UDCA 
are contradictory and based on 2 noncomparative28,29 
single-arm small non-RCTs. Doxycycline+TUDCA or 
UDCA are currently not approved by the EMA or FDA 
in transthyretin CA.
Further studies, preferentially large double-blinded 
RCTs, evaluating not only cardiac biomarkers or imag-
ing parameters but also hard clinical end points, such 
as all-cause mortality, cardiovascular mortality, and 
cardiovascular hospitalizations, will be needed to bet-
ter evaluate the efficacy of patisiran, inotersen, difluni-
sal, AG10, epigallocatechin-3-gallate, and doxycycline 
in patients with transthyretin CA.
This is an enthusiastic field of investigation. Many 
randomized, double-blind, placebo-controlled phase 
3 studies are currently underway and their results 
may change the paradigm of treatment of ATTR 
cardiomyopathy in the coming years. APOLLO B is 
evaluating patisiran in patients with ATTR cardiomy-
opathy (ATTRwt or ATTRv), considering 6-minute 
walk test as the primary end point and death and 
hospitalization outcomes as secondary end points 
at 12  months. The HELIOS-B study is evaluating 
another RNA interference agent, vutrisiran, with the 
advantage of a subcutaneous administration every 
3 months. This study will also include patients with 
ATTR cardiomyopathy, either ATTRwt or ATTRv, but 
the primary end point is the composite outcome of 
all-cause mortality and recurrent cardiovascular hos-
pitalizations at 30 months. The CARDIO-TTRansform 
trial is evaluating another antisense oligonucleotide, 
AKCEA-TTR-LRX, with the advantage of a lower fre-
quency of administration (every 4  weeks) and pos-
sibly of side effects compared with inotersen. This 
study will also include patients with ATTR cardiomy-
opathy, either ATTRwt or ATTRv, and the primary end 
point is cardiovascular mortality and clinical events at 
120 weeks. The ATTRIBUTE-CM study is evaluating 
AG10 in patients with ATTR cardiomyopathy (ATTRwt 
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walk test change from baseline at 12 months and all-
cause mortality and cardiovascular hospitalizations 
at 30 months.
On the other hand, past research has already led 
to the discontinuation of drugs in this field. The phase 
3 ENDEAVOUR study was prematurely terminated 
after a median of 6.71 months because of a mortal-
ity imbalance between revusiran, an RNA interference 
agent targeting transthyretin production, and placebo 
(12.9% versus 3.0%) in patients with variant trans-
thyretin CA. Most deaths were adjudicated as car-
diovascular caused by heart failure, consistent with 
the natural history of the disease. Although no clear 
causative mechanism could be identified, a role for re-
vusiran cannot be excluded and further development 
of this compound has been discontinued.32
Despite the intense ongoing investigation, there is 
still an evidence gap concerning particular subsets 
of patients who have been excluded from the stud-
ies, namely patients developing TTR CA after liver 
transplantation, patients with TTR CA presenting with 
advanced heart failure (NYHA class IV), and elderly pa-
tients with ATTRwt (older than 90  years). Studies on 
these subsets of patients are needed to be able to pro-
vide evidence-based recommendations on the use of 
these therapies in these patients.
Considering the high cost of some of these ther-
apies, cost-effectiveness studies should also be per-
formed in the near future. Kazi et al33 recently published 
a cost-effectiveness study for the use of tafamidis in 
ATTR cardiomyopathy, highlighting the need to lower 
the cost of tafamidis to be cost-effective.
Finally, studies are needed to assess whether the 
association of therapies with different mechanisms of 
action could improve the outcome of transthyretin CA.
Precision medicine might guide clinicians in the 
management of patients with transthyretin CA by pro-
viding the best therapy or combination of therapies for 
each patient, thereby maximizing effectiveness and re-
ducing undesirable effects.
CONCLUSIONS
This systematic review of the literature found and ana-
lyzed 4 RCTs and 16 non-RCTs in a total of 24 stud-
ies evaluating specific therapies for transthyretin CA. 
The available data allow us to recommend, with a 
high degree of certainty, the use of tafamidis in pa-
tients with transthyretin CA, both ATTRv and ATTRwt. 
Novel therapeutic targets including transthyretin gene 
silencers are currently under investigation. In addition, 
the systematic review of the available evidence does 
not support, at the present time, the use of diflunisal, 
AG10, doxycycline, or epigallocatechin-3-gallate in 
transthyretin CA.
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